Dr. Dauber is currently the Chief of Endocrinology at Children’s National Hospital. Dr. Dauber earned his MD and a Master’s degree in clinical investigation at Harvard Medical School. He completed his pediatrics residency, chief residency, and pediatric endocrinology fellowship training at Boston Children’s Hospital.

 

At Boston Children’s Hospital, Dr. Dauber began his research career in the laboratory of Joel Hirschhorn. Dr. Dauber’s work focuses on rare genetic causes of growth disorders and the use of next generation sequencing technologies to understand pediatric endocrine disorders. He has identified numerous genetic etiologies for short stature in addition to discovering that mutations in the MKRN3 and DLK1 genes are responsible for central precocious puberty. After his time in Boston, Dr. Dauber was the inaugural Program Director of The Cincinnati Center for Growth Disorders at Cincinnati Children’s Hospital. In 2018, Dr. Dauber moved to Washington, DC and assumed his current position of Chief of Endocrinology at Children’s National Hospital. Dr. Dauber is currently leading a clinical trial exploring the use of vosoritide in children with selected genetic causes of short stature.

 

In acknowledgment of his work, Dr. Dauber has earned multiple awards including young investigator awards from the Pediatric Endocrine Society, the American Society of Clinical Investigation and the European Society of Pediatric Endocrinology. In addition, he is the recipient of the Richard E. Weitzman Outstanding Early Career Investigator Award from the Endocrine Society.

Prof. Andrew Dauber has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grant support from BioMarin and Pfizer. Site investigator for Novo Nordisk Trial. Consulting for Novo Nordisk, QED and Pfizer.